By: 30 August 2018
Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm

In August 2018 Asarina Pharma applied to be listed on Nasdaq First North, generating significant interest. In September the company presents to investors at Aktiekvällen in Gothenburg, followed by further events in Stockholm.

“We’re developing the world’s first dedicated treatment for PMDD, the severest form of PMS,” says Peter Nordkild, CEO of Asarina Pharma. “PMDD is a painful condition that impacts one-in-20 women of a fertile age worldwide—as well as their families, friends and co-workers. I look forward to presenting our clinical data, and the major market potential for investors, in our two largest cities.”

PMDD (Premenstrual Dysphoric Disorder) is characterised by severe physical and emotional symptoms in the later part of the menstrual cycle. Current treatments provide only moderate relief of symptoms for most women, and many discontinue treatment to avoid side-effects.

“Sepranolone, the treatment we’re developing, has reduced PMDD symptoms by 80 per cent in a clinical study,” says Nordkild, “and this largely without side effects.”

A major Phase IIB study is currently underway in Europe, to verify the efficacy and safety of Sepranolone. Following that Asarina Pharma aims to launch the treatment onto the market as soon as 2023. Next year, 2019, the company begins a Phase IIA trial of Sepranolone as a treatment for menstrual migraine, another common, but rarely mentioned, condition that affects 1-in-5 women of a fertile age.

“The conditions are right for us to launch a first-in-class treatment onto a global market,” says Nordkild. “Given that effective competing treatments are almost non-existent, I hope that small and large investors alike are drawn to this extraordinary business opportunity, helping women worldwide affected by these disorders remain in control of their lives.”

For more information on Asarina Pharma, visit: